A Multidimensional Gene Expression Model that Accurately Predicts Tumor Response to Pembrolizumab or Nivolumab
D.R. Adkins(Washington University in St. Louis), Bonnie LaFleur(Vanderbilt University), Natalie A. LaFranzo(Cofactor Genomics (United States)), Ian Schillebeeckx(Cofactor Genomics (United States)), Peter Oppelt(Washington University in St. Louis), Kevin Palka(Washington University in St. Louis), Jeffrey Hiken(Cofactor Genomics (United States)), Jessica Ley(Washington University in St. Louis)
International Journal of Radiation Oncology*Biology*Physics
March 12, 2020
Cited by 2
Related Papers
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
|Cell Reports|2013|630
Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α
|Nature Chemical Biology|2010|488
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
|Clinical Cancer Research|2020|372